Neurofibromin 2 (Merlin)

A membrane protein homologous to the ERM (Ezrin-Radixin-Moesin) family of cytoskeleton-associated proteins which regulate physical properties of membranes. Alterations in neurofibromin 2 are the cause of NEUROFIBROMATOSIS 2.

Also Known As:

Networked: 497 relevant articles (12 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Giovannini, Marco: 23 articles (04/2015 - 08/2002)
2.	Morrow, David A: 22 articles (10/2015 - 06/2006)
3.	Gutmann, David H: 22 articles (01/2014 - 05/2002)
4.	Scirica, Benjamin M: 21 articles (08/2015 - 06/2006)
5.	Hanemann, C Oliver: 18 articles (07/2014 - 06/2003)
6.	Braunwald, Eugene: 17 articles (10/2015 - 06/2006)
7.	Murphy, Sabina A: 14 articles (10/2015 - 04/2007)
8.	Gutmann, D H: 13 articles (02/2011 - 06/2000)
9.	McClatchey, Andrea I: 10 articles (10/2015 - 05/2003)
10.	Morrison, Helen: 10 articles (05/2015 - 12/2002)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2010 - "Together, these recent advances have improved our basic understanding about merlin function, its regulation, and the major signaling pathways regulated by merlin and provided the foundation for future translation of these findings into the clinic for patients bearing the cancers in which merlin function and/or its downstream signaling pathways are impaired or altered." 07/27/2006 - "These results link merlin to the cell cycle control machinery and may help to understand its tumor suppressor function." 07/29/2014 - "Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study." 12/01/2012 - "Several studies have summarized the tumor intrinsic mutations in Merlin. " 02/01/2012 - "This study shows that, in addition to the tumor-suppressing activity of merlin, it also functions to maintain physiological angiogenesis in the nervous system by regulating antiangiogenic factors such as SEMA3F. "
2.	Acute Coronary Syndrome 04/25/2012 - "Here, we investigate how the approach of developing clinical models might be improved across three distinct patient populations (patients with acute coronary syndrome enrolled in the DISPERSE2-TIMI33 and MERLIN-TIMI36 trials, patients undergoing inpatient surgery in the National Surgical Quality Improvement Program registry, and patients undergoing percutaneous coronary intervention in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium registry). " 01/01/2012 - "Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial." 07/01/2009 - "Using data from the MERLIN-TIMI 36 trial, we assessed the association between the extent of angina after an acute coronary syndrome (ACS) and subsequent cardiovascular resource utilization among 5460 stable outpatients who completed the Seattle Angina Questionnaire at 4 months after an ACS and who were then followed for an additional 8 months. " 07/01/2009 - "Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial." 04/21/2009 - "Continuous ST-segment monitoring in contemporary acute coronary syndrome patients: the magic of MERLIN-TIMI 36."
3.	Ischemia 12/01/1998 - "Continuous ST-segment trends in leads II and V5 were recorded using Hewlett-Packard Merlin monitors postbypass until discharge from the postsurgical unit, and printouts were analyzed for episodes of ischemia. " 04/28/2009 - "Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial." 08/01/2015 - "We examined the 1-year incidence of recurrent cardiovascular (CV) events in the subgroup of patients with prior chronic angina (n = 3565) enrolled in the randomized, double-blind, placebo-controlled Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS (MERLIN)-Thrombolysis In Myocardial Infarction (TIMI) 36 trial who did or did not have a PCI within 30 days of the index event. " 03/23/2010 - "We measured plasma BNP in all available baseline samples (n = 4,543) among patients with non-ST-segment elevation ACS randomized to ranolazine or placebo in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days. " 04/28/2009 - "We investigated the antianginal effects of ranolazine in the subgroup of patients with prior chronic angina (n = 3,565, 54%) enrolled in the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) 36 trial of patients with acute coronary syndrome. "
4.	Neurilemmoma (Schwannoma) 01/01/2002 - "Using two-parameter FACS analysis we show that expression of wild-type merlin in NF2 cells led to significant reduction of proliferation and G0/G1 arrest in transduced schwannoma cells. " 09/29/2010 - "Consistent with the observation that over-expression of merlin arrested cell growth at G1-phase, the current study indicates that merlin exerts its antiproliferative effect, at least in part, by maintaining p21 expression, and loss of p21 is a prominent feature of merlin deficient schwannomas." 02/08/2007 - "In the present study, we show that increased expression of wild-type merlin in Tr6BC1 schwannoma cells inhibits HA binding to CD44. " 09/01/2015 - "To date, only merlin has been identified as a hallmark or pathogenesis of both sporadic and NF2-related schwannomas. " 04/01/2014 - "Merlin has multiple functions, including within the nucleus and at the cell membrane, and this review summarizes our current understanding of the mechanisms by which merlin loss is involved in schwannoma pathogenesis, highlighting potential areas for therapeutic intervention. "
5.	Myocardial Infarction 05/01/2007 - "The MERLIN trial compared rPCI and a conservative strategy in patients with failed fibrinolysis complicating ST-segment elevation myocardial infarction. " 10/01/2005 - "To report one year results of the MERLIN (Middlesbrough early revascularisation to limit infarction) trial, a prospective randomised trial comparing the strategy of coronary angiography and urgent revascularisation with conservative treatment in patients with failed fibrinolysis complicating ST segment elevation myocardial infarction (STEMI). " 07/21/2004 - "A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial." 08/01/2015 - "We examined the 1-year incidence of recurrent cardiovascular (CV) events in the subgroup of patients with prior chronic angina (n = 3565) enrolled in the randomized, double-blind, placebo-controlled Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS (MERLIN)-Thrombolysis In Myocardial Infarction (TIMI) 36 trial who did or did not have a PCI within 30 days of the index event. " 03/23/2010 - "We measured plasma BNP in all available baseline samples (n = 4,543) among patients with non-ST-segment elevation ACS randomized to ranolazine or placebo in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days. "

Related Drugs and Biologics

1.	ranolazine
2.	bevacizumab
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
5.	nutlin 3
6.	Neurofibromin 2 (Merlin)
7.	Biological Markers (Surrogate Marker)
8.	Brain Natriuretic Peptide (Natrecor)
9.	Agar
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Angioplasty (Angioplasty, Transluminal)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Drug Therapy (Chemotherapy)
4.	Axotomy
5.	Transplantation (Transplant Recipients)